Soma S Nag
Affiliation: Merck Research Laboratories
- Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart diseaseSoma S Nag
Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania, USA
Am J Cardiol 95:862-4. 2005..The overall lipid-lowering therapy treatment rate was 38% and the estimated lipid treatment gap (percent needing treatment who were not receiving it) was 62%...
- LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMOSoma S Nag
Merck and Co, Inc, 770 Broad Street, West Point, PA, USA
J Manag Care Pharm 13:652-63. 2007..Patients with coronary heart disease or diabetes are at high risk of coronary events and are particularly important target groups for monitoring and dose adjustment of lipid-modifying drug therapy...
- Reassessment of cardiovascular risk in diabetesJonathan R Jaffe
Merck and Co, Inc, Sumneytown Pike, West Point, Pennsylvania 19486, USA
Curr Opin Lipidol 17:644-52. 2006..SUMMARY: The majority of adults with diabetes have a substantially greater risk compared with those without diabetes and a small percentage has very high risk. A minority of individuals may have considerably lower 10-year risk...
- Trends in lipid management among patients with diabetesKaan Tunceli
Center for Health Services Research, Henry Ford Health System, Detroit, Michigan 48202, USA
Endocr Pract 12:380-7. 2006..Particular attention may be warranted to ensure that patients with diabetes receive lipid-lowering agents not only after a cardiovascular event but also before such an event occurs...